Skip to main content
. 2020 Oct 20;11:1015. doi: 10.3389/fneur.2020.01015

Table 3.

Mean change in plasma concentrations of C-reactive protein (CRP), plasma concentrations of cytokines and plasma concentrations of biomarkers of intestinal permeability from Visit 2 to Visit 3.

Placebo Probiotic p-value
N Mean (SD) and Median (range)a N Mean (SD) and Median (range)a
Biomarkers of Inflammation
CRP (mg/L) 14 0.113 (1.2)
0.09 (−2.3, 2.4)
10 −0.625 (1.1)
−0.565 (−2.3, 1.5)
0.056
IFNγ (pg/ml) 14 0.36 (1.2)
0.04 (−1.4, 3.9)
9 −0.33 (1.2)
−0.04 (−3.1, 1.1)
0.22
IL1α (pg/ml) 14 0.98 (4.0)
0.28 (−4.4, 12.7)
9 −1.6 (11.2)
1.64 (−30.4, 9.6)
0.45
IL1β (pg/ml) 14 0.70 (2.7)
0.04 (−3.5, 9.1)
9 −0.25 (2.5)
−0.03 (−6.1, 3.3)
0.37
IL2 (pg/ml) 14 0.02 (0.34)
−0.02 (−0.60, 0.81)
9 −0.12 (1.3)
0 (−3.4, 1.3)
0.51
IL6 (pg/ml) 14 0.22 (2.4)
−0.10 (−5.1, 4.0)
9 −0.07 (7.7)
−0.24 (−13.5, 16.3)
0.64
IL8 (pg/ml) 14 −4.8 (11.2)
−0.49 (−39.2, 3.6)
9 1.4 (5.9)
1.1 (−8.8, 11.4)
0.12
IL10 (pg/ml) 14 0.15 (0.85)
0.09 (−1.4, 2.2)
9 −0.23 (2.0)
−0.23 (−3.0, 2.4)
0.72
IL12p70 (pg/ml) 14 −1.6 (9.3)
−0.41 (−28.5, 11.2)
9 −10.1 (46.2)
−0.61 (−129, 34.3)
0.89
IL-6:IL-10 ratio 14 −0.08 (1.0)
−0.004 (−3.2, 1.6)
9 −0.003 (0.97)
−0.12 (−0.7, 1.6)
0.52
TNFα (pg/ml) 14 −0.62 (1.4)
−0.27 (−3.7, 1.3)
9 −2.1 (8.2)
0 (−23.7, 3.2)
0.26
Intestinal Permeability
DAO (ng/ml) 10 −0.11 (0.24)
−0.08 (−0.55, 0.29)
8 0.03 (0.12)
0.08 (−0.12, 0.16)
0.17
IFABP (pg/ml) 12 −0.09 (0.45)
−0.17 (−1.0, 0.72)
10 −0.04 (0.16)
−0.03 (−0.35, 0.21)
0.54
a

Negative numbers indicate a decrease from Visit 2 to Visit 3. Wilcoxon rank-sum test was used to compare the change from Visit 2 to Visit 3 between the Placebo and Probiotic groups. CRP, C-reactive protein; DAO, D-amino acid oxidase; IFABP, intestinal fatty acid binding protein; IFNγ, interferon gamma; IL, interleukin; mg/L, milligrams/liter; ng/ml, nanograms/ milliliter; pg/ml, picograms/ milliliter; TNFα, tumor necrosis factor alpha.